Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification

por Meedendorp, Arenda D., ter Elst, Arja, ’t Hart, Nils A., Groen, Harry J. M., Schuuring, Ed, van der Wekken, Anthonie J.
Publicado 2018

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients

por Koele, Simon E., van Beek, Stijn W., van der Wekken, Anthonie J., Piet, Berber, van den Heuvel, Michel M., ter Heine, Rob
Publicado 2021

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nat...

por Gijtenbeek, Rolof G.P., Damhuis, Ronald A.M., van der Wekken, Anthonie J., Hendriks, Lizza E.L., Groen, Harry J.M., van Geffen, Wouter H.
Publicado 2023

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

por Wei, Jiacong, van der Wekken, Anthonie J., Saber, Ali, Terpstra, Miente M., Schuuring, Ed, Timens, Wim, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke, Kok, Klaas
Publicado 2018

CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor

por Liu, Bin, Song, Shanshan, Setroikromo, Rita, Chen, Siwei, Hu, Wenteng, Chen, Deng, van der Wekken, Anthonie J., Melgert, Barbro N., Timens, Wim, van den Berg, Anke, Saber, Ali, Haisma, Hidde J.
Publicado 2019

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

por Li, Weiting, Kok, Klaas, Tan, Geok Wee, Meng, Pei, Mastik, Mirjam, Rifaela, Naomi, Scherpen, Frank, Hiltermann, T. Jeroen N., Groen, Harry J. M., van der Wekken, Anthonie J., van den Berg, Anke
Publicado 2022

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer

por Saber, Ali, van der Wekken, Anthonie J., Kerner, Gerald S. M. A., van den Berge, Maarten, Timens, Wim, Schuuring, Ed, ter Elst, Arja, van den Berg, Anke, Hiltermann, T. Jeroen N., Groen, Harry J. M.
Publicado 2016

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

por Saber, Ali, van der Wekken, Anthonie J., Kok, Klaas, Terpstra, M. Martijn, Bosman, Lisette J., Mastik, Mirjam F., Timens, Wim, Schuuring, Ed, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke
Publicado 2016

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

por Boonstra, Pieter A., Wind, Thijs T., van Kruchten, Michel, Schuuring, Ed, Hospers, Geke A. P., van der Wekken, Anthonie J., de Groot, Derk-Jan, Schröder, Carolien P., Fehrmann, Rudolf S. N., Reyners, Anna K. L.
Publicado 2020

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

por Koopman, Bart, Cajiao Garcia, Betzabel N., Kuijpers, Chantal C. H. J., Damhuis, Ronald A. M., van der Wekken, Anthonie J., Groen, Harry J. M., Schuuring, Ed, Willems, Stefan M., van Kempen, Léon C.
Publicado 2021

Molecular imaging to support cancer immunotherapy

por van de Donk, Pim P, Oosting, Sjoukje F, Knapen, Daan G, van der Wekken, Anthonie J, Brouwers, Adrienne H, Lub-de Hooge, Marjolijn N, de Groot, Derk-Jan A, de Vries, Elisabeth GE
Publicado 2022

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

por Wei, Jiacong, Rybczynska, Anna A., Meng, Pei, Terpstra, Martijn, Saber, Ali, Sietzema, Jantine, Timens, Wim, Schuuring, Ed, Hiltermann, T. Jeroen N., Groen, Harry J. M., van der Wekken, Anthonie J., van den Berg, Anke, Kok, Klaas
Publicado 2020

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Inser...

por Christopoulos, Petros, Girard, Nicolas, Proto, Claudia, Soares, Marta, Lopez, Pilar Garrido, van der Wekken, Anthonie J., Popat, Sanjay, Diels, Joris, Schioppa, Claudio A., Sermon, Jan, Rahhali, Nora, Pick-Lauer, Corinna, Adamczyk, Agnieszka, Penton, James, Wislez, Marie
Publicado 2023

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

por van de Donk, Pim P, Kist de Ruijter, Laura, Lub-de Hooge, Marjolijn N, Brouwers, Adrienne H, van der Wekken, Anthonie J, Oosting, Sjoukje F, Fehrmann, Rudolf SN, de Groot, Derk Jan A, de Vries, Elisabeth GE
Publicado 2020

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

por Li, Jingjing, Zhang, Bin, Zhang, Yu, Xu, Feng, Zhang, Zhenfa, Shao, Lin, Yan, Chunhe, Ulivi, Paola, Denis, Marc G., Christopoulos, Petros, Thomas de Montpréville, Vincent, Bernicker, Eric H., van der Wekken, Anthonie J., Wang, Changli, Yue, Dongsheng
Publicado 2021

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

por Wei, Jiacong, Meng, Pei, Terpstra, Miente Martijn, van Rijk, Anke, Tamminga, Menno, Scherpen, Frank, ter Elst, Arja, Alimohamed, Mohamed Z., Johansson, Lennart F., Stigt, Jos, Gijtenbeek, Rolof P. G., van Putten, John, Hiltermann, T. Jeroen N., Groen, Harry J. M., Kok, Klaas, van der Wekken, Anthonie J., van den Berg, Anke
Publicado 2021

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

por Zou, Zihua, Gu, Yangchun, Liang, Li, Hao, Xuezhi, Fan, Chengjuan, Xin, Tao, Zhao, Songchen, Liu, Ziling, Guo, Ye, Ma, Kewei, Li, Haojing, Zhang, Cuiying, Shan, Li, Zhang, Yan, Dong, Guilan, Peng, Yumei, Shen, Fangfang, Song, Xia, Christopoulos, Petros, van der Wekken, Anthonie J., Okuda, Katsuhiro, Ekman, Simon, Xing, Puyuan, Li, Junling
Publicado 2022

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

por Veerman, G.D. Marijn, Boosman, Rene J., Jebbink, Merel, Oomen-de Hoop, Esther, van der Wekken, Anthonie J., Bahce, Idris, Hendriks, Lizza E.L., Croes, Sander, Steendam, Christi M.J., de Jonge, Evert, Koolen, Stijn L.W., Steeghs, Neeltje, van Schaik, Ron H.N., Smit, Egbert F., Dingemans, Anne-Marie C., Huitema, Alwin D.R., Mathijssen, Ron H.J.
Publicado 2023

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

por Drilon, Alexander, Horan, Joshua C., Tangpeerachaikul, Anupong, Besse, Benjamin, Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Camidge, D. Ross, van der Wekken, Anthonie J., Nguyen-Phuong, Linh, Acker, Adam, Keddy, Clare, Nicholson, Katelyn S., Yoda, Satoshi, Mente, Scot, Sun, Yuting, Soglia, John R., Kohl, Nancy E., Porter, James R., Shair, Matthew D., Zhu, Viola, Davare, Monika A., Hata, Aaron N., Pelish, Henry E., Lin, Jessica J.
Publicado 2023

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, mul...

por Meertens, Marinda, Muntinghe-Wagenaar, M. Benthe, Sikkema, Barend J., Lopez-Yurda, Marta, Retèl, Valesca P., Paats, Marthe S., Ter Heine, Rob, Schuuring, Ed, Timens, Wim, Touw, Daan J., van Boven, Job F. M., de Langen, Adrianus. J., Hashemi, Sayed M. S., Hendriks, Lizza E. L., Croes, Sander, van den Heuvel, Michel M., Dingemans, Anne-Marie C., Mathijssen, Ron H. J., Smit, Egbert F., Huitema, Alwin D. R., Steeghs, Neeltje, van der Wekken, Anthonie J.
Publicado 2023